Clinical Pharmacogenomic of Metformin in Egyptian Patients with Insulin Resistance

Pharmacogenomics is rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. The aim of this study was to explore the association of genetic mutation and /or polymorphism of genes related to therapeutics used in the treatment of insulin resistance IR. This study was aimed to investigate the association of rs2289669 variants in SLC47A1 gene response to metformin after 6 months follow up in Egyptian patients with insulin resistance IR. This study included 70 patients from those attending the outpatient clinics Diabetic Department, National Institute of Diabetes and Endocrinology in the period from 03/02/2022 to 1/2/2023 approved (NO. IDE 00272). Metformin 1000 mg and Vildagliptin 50 mg were given as treatment for 6 months, Genotyping of the rs2289669 variant of SLC47A1 gene was performed using the restriction fragment length polymorphism–PCR (RFLP–PCR) method. Results as regarding decrease in HbA1c, TC, TC/HDL, LDL/HDL there was significant difference between the three different genotypes GG, GA, AA of SLC47A1 rs2289669 variant (P<0.05).also there was no significant difference in response of glycemic and lipid parameters to metformin 1000 mg among different genotypic groups after 6 months (p > 0.05) Except HbA1c, TC, TC/HDL, LDL/HDL there was significant difference between the three different genotypes of SLC47A1 rs2289669 variant (P<0.05) . The study results indicate that effects of variation in SLC47A1 (rs2289669) on the clinical efficacy of metformin were important in treatment of insulin resistance.